Amylin Pharma (AMLN) Reports Q4 GAAP Loss of $3.15/Share

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q4 GAAP loss of $3.15, which does not compare to the analyst estimate of ($0.08). The company posted a loss per share of 13 cents during the same quarter last year. Revenue for the quarter came in at $164.9 million versus the consensus estimate of $163.64 million.

For earnings history and earnings-related data on Amylin Pharmaceuticals, Inc. (AMLN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Marchex (MCHX) Reports In-Line Q2 EPS
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c